×
About 493 results

ALLMedicine™ Alagille Syndrome Center

Research & Reviews  178 results

Atorvastatin Therapy on Xanthoma in Alagille Syndrome
https://clinicaltrials.gov/ct2/show/NCT05488067

Aug 4th, 2022 - Alagille syndrome (ALGS, OMIM 118450) is an important cause of chronic cholestasis in children, and the incidence rate is about 1:30000~1:50000. Most patients with ALGS have hypercholesterolemia. In severe cases, multiple xanthomas can be seen, an...

Management of Patients with Alagille Syndrome Undergoing Living Donor Liver Transplanta...
https://doi.org/10.12659/AJCR.936513
The American Journal of Case Reports; Alqahtani OJ, Ahmad RN et. al.

Aug 4th, 2022 - BACKGROUND Alagille syndrome (AGS) is a rare genetic disease characterized by 5 typical features: peculiar facial anomaly, posterior embryotoxon, chronic cholestasis, butterfly-like vertebral-arch defects, and cardiovascular malformations. AGS in ...

Alagille Syndrome: Current Understanding of Pathogenesis, and Challenges in Diagnosis a...
https://doi.org/10.1016/j.cld.2022.03.002
Clinics in Liver Disease; Ayoub MD, Kamath BM

Jul 23rd, 2022 - Alagille syndrome (ALGS) is a complex heterogenous disease with a wide array of clinical manifestations in association with cholestatic liver disease. Major clinical and genetic advancements have taken place since its first description in 1969. Ho...

Pediatric Liver Transplant Outcomes in Alagille Syndrome: A Linked Database Analysis.
https://doi.org/10.1097/01.tp.0000812776.48064.0e
Transplantation Black K, Ziogas IA et. al.

Jun 16th, 2022 - Pediatric Liver Transplant Outcomes in Alagille Syndrome: A Linked Database Analysis.|2022|Black K,Ziogas IA,Thurm C,Hall M,Thor Hafberg E,|surgery,adverse effects,

see more →

Drugs  1 results see all →

Clinicaltrials.gov  12 results

Atorvastatin Therapy on Xanthoma in Alagille Syndrome
https://clinicaltrials.gov/ct2/show/NCT05488067

Aug 4th, 2022 - Alagille syndrome (ALGS, OMIM 118450) is an important cause of chronic cholestasis in children, and the incidence rate is about 1:30000~1:50000. Most patients with ALGS have hypercholesterolemia. In severe cases, multiple xanthomas can be seen, an...

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
https://clinicaltrials.gov/ct2/show/NCT04674761

Mar 31st, 2022 - Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
https://clinicaltrials.gov/ct2/show/NCT05035030

Mar 10th, 2022 - Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
https://clinicaltrials.gov/ct2/show/NCT02047318

Nov 19th, 2021 - The purpose of this extension study is to determine the long-term safety and tolerability of an investigational treatment (LUM001 also known as Maralixibat) in children with ALGS who have completed participation in a core LUM001 treatment protocol...

see more →

News  5 results

IBAT Inhibitors: The Medication That Patients With Pruritus Were Itching to Try
https://www.medscape.com/viewarticle/974182

May 23rd, 2022 - Pruritus is a prime clinical expression of cholestatic diseases in children and adults. In my clinical experience, there was no more poignant depiction of the ravages of cholestatic pruritus than that of an 11-year-old girl with Alagille syndrome ...

Mirum's Oral Drug Becomes First US-Approved Alagille Syndrome Therapy
https://www.medscape.com/viewarticle/959976

Sep 29th, 2021 - Mirum Pharmaceuticals Inc said its drug became the first U.S. approved therapy for treating itching in patients with rare liver disorder Alagille syndrome (ALGS), and would be available for distribution immediately. Shares of the company were brie...

Progress in Fatty Liver and Pediatric Liver Disease
https://www.staging.medscape.com/viewarticle/886923

Oct 11th, 2017 - WASHINGTON, DC — Advances in the treatment of nonalcoholic steatohepatitis (NASH) — including results from a phase 2 trial of a liver-targeted selective inhibitor of acetyl-CoA carboxylase — will be in the spotlight here at The Liver Meeting 2017:...

Progress in Fatty Liver and Pediatric Liver Disease
https://www.medscape.com/viewarticle/886923

Oct 11th, 2017 - WASHINGTON, DC — Advances in the treatment of nonalcoholic steatohepatitis (NASH) — including results from a phase 2 trial of a liver-targeted selective inhibitor of acetyl-CoA carboxylase — will be in the spotlight here at The Liver Meeting 2017:...

Progress Noted in Treatment of Several Common Liver Diseases
https://www.medscape.com/viewarticle/861425_6

Apr 8th, 2016 - Intrahepatic Cholestasis Neonatal cholestasis results from a heterogeneous group of intrahepatic disorders caused by mutations in several genes.[28] Recent advances in the understanding of the molecular basis of genetic cholestatic syndromes, such...

see more →

Patient Education  1 results see all →